☆ 4.7 Article

Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Immunomodulation for hepatocellular carcinoma therapy: current challenges

Zuzana Macek Jilkova et al.

Summary: novel immunotherapies, such as immune-checkpoint inhibitors, have changed the landscape of systemic cancer treatment. However, the response rate of immune-checkpoint inhibitors in hepatocellular carcinoma (HCC) remains low. Recent findings suggest that the immune contexture and cause of HCC are crucial factors influencing the efficacy of immunotherapies. Locoregional therapies can induce immune changes and when combined with immunotherapies, they may help prevent recurrence. Transarterial therapies may improve outcomes in multifocal HCC.

CURRENT OPINION IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications

Medine Zeynep Gungor et al.

Summary: The TGF-beta signaling pathway has a dual and opposing role in hepatocellular carcinoma (HCC), acting as a tumor suppressor in the early stages and a promoter of tumor progression in the late stages. Therefore, targeting the TGF-beta signaling pathway is a promising therapeutic strategy for HCC.

CANCERS (2022)

添加到收藏夹

Article Oncology

Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib

Che-Jui Yang et al.

Summary: AKT/ERK signaling and anti-apoptosis effects are crucial in the progression of hepatocellular carcinoma (HCC). Lenvatinib and Amentoflavone have the potential to alleviate HCC growth, and their combination may result in stronger suppression.

ANTICANCER RESEARCH (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma

Xiang-Peng Tan et al.

Summary: This study discovered the highly expressed FXYD5 in sorafenib-resistant HCC cells and its higher expression level in HCC tissues compared to par-acancerous tissues. The downregulation of FXYD5 reversed the resistance of Huh7/sora cells to sorafenib, while overexpression of FXYD5 reduced the sensitivity of HCC cells to sorafenib. Additionally, abnormal activation of the Akt/mTOR signaling pathway was found in Huh7/sora cells, and MK2206, an Akt inhibitor, increased the sensitivity of HCC cells to sorafenib. The expression level of p-Akt was positively correlated with the expression of FXYD5 in HCC tissues.

EUROPEAN JOURNAL OF PHARMACOLOGY (2022)

添加到收藏夹

Article Oncology

MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis

Chaoran Shi et al.

Summary: Hepatocellular cancer (HCC) is a lethal subtype of liver cancer, and effective therapeutics are lacking. Understanding and targeting cancer stem cells (CSCs) can revolutionize cancer management. Maelstrom (MAEL) is implicated in the regulation of CSC phenotypes, and our study demonstrates that MAEL positively regulates cancer stem-cell-like properties in HCC. MAEL silencing enhances tumor cells' sensitivity to sorafenib. Our study also reveals the involvement of the MAEL-dependent PGST2/IL8/AKT/STAT3 signaling pathway in the regulation of stemness. Targeting the MAEL/PGST2 axis may be a potential therapeutic strategy against CSC and sorafenib resistance in HCC.

CANCERS (2022)

添加到收藏夹

Article Cell Biology

Chronic Intermittent Hypoxia Increases Cell Proliferation in Hepatocellular Carcinoma

Lydie Carreres et al.

Summary: This study investigated the impact of OSA-related chronic intermittent hypoxia on HCC progression using a HCC model. The study found that intermittent hypoxia further increased HCC cell proliferation, potentially contributing to an increased risk of HCC progression.

CELLS (2022)

添加到收藏夹

Review Medicine, General & Internal

Hepatocellular carcinoma

Arndt Vogel et al.

Summary: Hepatocellular carcinoma is a common cancer worldwide, with non-alcoholic fatty liver disease becoming a dominant cause. Treatment options are varied, including surgery, radiation, and medication. With the approval of new drugs and the development of immunotherapy, the outlook for hepatocellular carcinoma patients has improved, but the optimal sequencing of drugs and predictive biomarkers still need further research.

LANCET (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment

Mariam Mroweh et al.

Summary: Hepatocellular carcinoma (HCC) is a common cause of cancer-related deaths worldwide, with its incidence on the rise. Chronic inflammation plays a key role in hepatocarcinogenesis, and inhibition of Akt has effects on both cancer cells and the tumor microenvironment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Oncology

DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma

Keerthi Kurma et al.

Summary: Hepatocellular carcinoma (HCC) is the most common type of liver cancer, often associated with liver fibrosis or cirrhosis from chronic liver injuries. The liver's immune system plays a crucial role in disease progression towards HCC. The DEN-induced rat model of HCC exhibits molecular characteristics similar to human HCC, especially those with high proliferation, making it a valuable tool for preclinical testing.

CANCERS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma

Eun Jin Sun et al.

Summary: This review article discusses the pivotal role of the PI3K/Akt/mTOR pathway in HCC, focusing on its impact on cellular processes and providing an update on the ongoing clinical development of therapies targeting this pathway for HCC treatments.

BIOMEDICINES (2021)

添加到收藏夹

Review Oncology

The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review

Federica Rascio et al.

Summary: The PI3K/Akt pathway plays a crucial role in drug resistance in cancer by impacting tumor cell growth and metastasis through different signaling pathways. Its multi-level deregulation contributes to resistance in various cancer types. Understanding the pathway is essential in developing potential inhibition strategies for overcoming drug resistance.

CANCERS (2021)

添加到收藏夹

Article Oncology

A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity

Eleftherios Kostaras et al.

BRITISH JOURNAL OF CANCER (2020)

添加到收藏夹

Review Oncology

Molecular Bases of Drug Resistance in Hepatocellular Carcinoma

Jose J. G. Marin et al.

CANCERS (2020)

添加到收藏夹

Article Cell Biology

Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models

Suraj U. Hettiarachchi et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma

Zuzana Macek Jilkova et al.

Oncotarget (2018)

添加到收藏夹

Article Oncology

Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma

Gael S. Roth et al.

MOLECULAR CANCER THERAPEUTICS (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

Maximising the potential of MKT inhibitors as anti-cancer treatments

Jessica S. Brown et al.

PHARMACOLOGY & THERAPEUTICS (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

Yi Yu et al.

PLOS ONE (2015)

添加到收藏夹

Article Oncology

Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma

Imge Kunter et al.

ONCOLOGY REPORTS (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension?

Dominique Thabut et al.

JOURNAL OF HEPATOLOGY (2010)

添加到收藏夹

Article Oncology

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

Ledu Zhou et al.

MEDICAL ONCOLOGY (2010)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

Timothy A. Yap et al.

CURRENT OPINION IN PHARMACOLOGY (2008)

添加到收藏夹

Review Gastroenterology & Hepatology

Molecular targeted therapies in hepatocellular carcinoma

Josep M. Llovet et al.

HEPATOLOGY (2008)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structure, regulation and function of PKB/AKT - a major therapeutic target

M Hanada et al.

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.